Methylin ER en es it fr

Methylin ER Brand names, Methylin ER Analogs

Methylin ER Brand Names Mixture

  • No information avaliable

Methylin ER Chemical_Formula


Methylin ER RX_link

Methylin ER fda sheet

Methylin_ER FDA

Methylin ER msds (material safety sheet)

Methylin_ER MSDS

Methylin ER Synthesis Reference

M. Hartmann, L. Panizzon, U.S. Pat. 2,507,631 (1950)

Methylin ER Molecular Weight

233.306 g/mol

Methylin ER Melting Point


Methylin ER H2O Solubility


Methylin ER State


Methylin ER LogP


Methylin ER Dosage Forms

Tablets; Tablets (sustained release)

Methylin ER Indication

For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.

Methylin ER Pharmacology

Methylphenidate is a central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of dextroamphetamine.

Methylin ER Absorption

Readily absorbed in a biphasic manner. It reaches peak absorption at approximately two hours for the first phase and five hours for the second phase. Bioavailability is low (approximately 30%)

Methylin ER side effects and Toxicity

Symptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes. LD50=190mg/kg (orally in mice)

Methylin ER Patient Information

Methylin ER Organisms Affected

Humans and other mammals